If Ab­b­Vie ex­ec­u­tives are both­ered by grow­ing threats to their im­munol­o­gy pow­er­house, they aren't let­ting on.

Ear­li­er this year, an­a­lysts were pon­der­inghow the com­pa­ny’s...

Mod­er­na will need an­oth­er norovirus sea­son to ad­e­quate­ly test the ef­fi­ca­cy of its vac­cine, say­ing that it is stand­ing up an ad­di­tion­al tri­al group so...

HH­S' Health Re­sources and Ser­vices Ad­min­is­tra­tion un­veiled de­tails of a re­vised 340B re­bate pi­lot, which will let some drug man­u­fac­tur­ers de­ny re­bates for a small...

An an­ti-in­flam­ma­to­ry drug from No­vo Nordisk un­ex­pect­ed­ly failed in a Phase 3 study that aimed to prove a link be­tween car­dio­vas­cu­lar in­flam­ma­tion and heart dis­ease...

In the city that nev­er sleeps, a sleep ap­nea drug de­vel­op­er has se­cured a $192 mil­lion IPO af­ter more than three years of eye­ing a...